ArticleFrontiers in public health2026

Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk.

Longbing Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.